Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale

por Andersson, Yvonne, Fleten, Karianne G., Abrahamsen, Torveig W., Reed, Wenche, Davidson, Ben, Flatmark, Kjersti
Publicado 2021

MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer

por Andersson, Yvonne, Haavardtun, Synne Ihler, Davidson, Ben, Dørum, Anne, Fleten, Karianne G., Fodstad, Øystein, Flatmark, Kjersti
Publicado 2017

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma

por Fleten, Karianne G, Flørenes, Vivi Ann, Prasmickaite, Lina, Hill, Oliver, Sykora, Jaromir, Mælandsmo, Gunhild M, Engesæter, Birgit
Publicado 2016

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors

por Seip, Kotryna, Fleten, Karianne G., Barkovskaya, Anna, Nygaard, Vigdis, Haugen, Mads H., Engesæter, Birgit Ø., Mælandsmo, Gunhild M., Prasmickaite, Lina
Publicado 2016

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei

por Flatmark, Kjersti, Torgunrud, Annette, Fleten, Karianne G, Davidson, Ben, Juul, Hedvig V, Mensali, Nadia, Lund-Andersen, Christin, Inderberg, Else Marit
Publicado 2021

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

por Repetto-Llamazares, Ada H. V., Larsen, Roy H., Patzke, Sebastian, Fleten, Karianne G., Didierlaurent, David, Pichard, Alexandre, Pouget, Jean Pierre, Dahle, Jostein
Publicado 2015